In pediatric gliomas, 80% of the high-grade and 50% of low-grade gliomas have enhanced activation of two of the major downstream targets of mTORC1, S6 and 4EBP1, which correlates with decrease in progression-free survival independently of tumor grade [227]. The gene discussed is EIF4EBP1; the disease is central nervous system cancer.